Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zejun Wang

Showing results (171-180 of 173) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 173 results.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2020
Effectiveness of convalescent plasma therapy in severe COVID-19 patientsKai Duan, Bende Liu, Cesheng Li, et al.
Nature Medicine|March 27, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 18

Showing results (171-180 of 173) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 173 results.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2020
Effectiveness of convalescent plasma therapy in severe COVID-19 patientsKai Duan, Bende Liu, Cesheng Li, et al.
Nature Medicine|March 27, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 18